Anavex Life Sciences Corp (AVXL)

[falconer66a]

Good Question --- Age and/or Genetics

What causes, then, the mitochondria to no longer function properly? What causes them to no longer connect effectively with endoplasmic reticula? Two probable reasons (and there may be more).

The first is simple age. No one can contest that by middle age, organs and tissues no longer function as well as in the first half of life. Mechanisms weaken. Likewise, in neurons. The structural chemistry holding things, literally, together, weakens. Anavex 2-73 re-connects and supports the otherwise weakened sub-cellular structure in the neuron.

In other cases, particularly with early-onset Alzheimer's, defective genetics prevents full structural architecture and function.

And, as the genomic analyses performed in the Australian trial have apparently discovered, there are specific genetic patterns that correlate very positively with Anavex 2-73 efficacy. The neuron aging process has genetic controlling components, which Anavex Life Sciences Corp has now discovered. With these predictive genomic data, the company will be able to select for the upcoming clinical trial of Anavex 2-73 only participants who have those specific Alzheimer's-prone, Anavex 2-73-favorable genes.

The trial process is now stacked in Anavex's favor. Only those who have Alzheimer's genes open to Anavex 2-73 efficacy will be allowed to participate in the trial. Precise stuff. "Precision medicine."

Ponder, then, who will benefit.